New clinical data supports efficacy of OTC PE treatment PreBoost

MIAMI — Veru Healthcare on Saturday announced positive results from a Phase 4 clinical study of its proprietary product PreBoost (topical 4% benzocaine wipes) for the management of premature ejaculation. Data showed that PreBoost wipes statistically and significantly improved both objective and subjective symptoms of PE when compared to placebo wipes.



Results were selected for inclusion in the American Urological Association’s Annual Meeting Press Conference, held Saturday morning in Boston. The data will also be shared during a podium presentation on May 16, Veru Healthcare noted.



“Premature ejaculation or PE is the most common sexual dysfunction, affecting one in four men, yet we have limited options that really help men manage it,” stated study investigator and presenter Ridwan Shabsigh, chairman surgery, SBH Health System and professor clinical urology at Weill-Cornell Medical School. “These data represent the first ever placebo-controlled clinical study of medicines available in this class of products.”



After treatment with PreBoost, 82% of men were no longer considered to have PE while being treated and reported a statistically significant better sense of control, confidence, satisfaction, pleasure, increased length of intercourse and reduced frustration. Treatment was well tolerated and no transference of product was reported.



“We’re excited about these clinical data and what our product can do for men who have really had no options and desire a simple solution to PE,” commented Mitchell Steiner, president and CEO Veru Healthcare. “These Phase 4 data represent the first clinical study ever to show clinical data of an OTC product for the management of premature ejaculation.”